Follow the Data: Applying PSI to CAR T-cell product release, in a way that correlates to in vivo activity1

Research Area: Cell engineering & therapy

Development Stage: Prediction

Goal: Identify pre-infusion correlates to in vivo active of cell therapy and patient outcome

[unex_ce_button id="content_10khx0ih9,column_content_611g46odk" button_text_color="#ffffff" button_font="bold" button_font_size="18px" button_width="auto" button_alignment="right" button_text_spacing="1px" button_bg_color="#24b7d8" button_padding="15px 30px 15px 30px" button_border_width="0px" button_border_color="#24b7d8" button_border_radius="0px" button_text_hover_color="#ffffff" button_text_spacing_hover="1px" button_bg_hover_color="#84c9d8" button_border_hover_color="#84c9d8" button_link="https://www.isoplexis.com/request-a-seminar" button_link_type="url" button_link_target="_blank" has_container="" in_column="1"]Request a seminar
to follow our data >[/ce_button]

How our single-cell systems are making a difference

Solution:  IsoPlexis' PSI is able to stratify responders and non-responders

Finding: Polyfunctional strength was found to correlate with objective response to CAR-T cell therapy, where other pre-infusion metrics did not

Follow the data

PSI of the pre-infusion CAR-T cell products showed significant correlation with the objective response of patients. The PSI, measured across a cohort of 20 patients, combined the CD4+ and CD8+ CAR-T response to CD19-K562 stimulation.

The average PSI of the responder subgroup was more than twice as high as the PSI of the non-responders, a difference that was shown to be statistically significant (p = 0.0119).1

[unex_ce_button id="content_om95el0ye,column_content_g32kkdowi" button_text_color="#424242" button_font="bold" button_font_size="18px" button_width="auto" button_alignment="right" button_text_spacing="1px " button_bg_color="#c9c9c9" button_padding="15px 30px 15px 30px" button_border_width="0px" button_border_color="#c9c9c9" button_border_radius="0px" button_text_hover_color="#424242" button_text_spacing_hover="1px" button_bg_hover_color="#e8e8e8" button_border_hover_color="#e8e8e8" button_link="https://www.isoplexis.com/CellT-P" button_link_type="url" button_link_target="_blank" has_container="" in_column="1"]Download application note
to learn more >[/ce_button]

IsoPlexis finds critical differences

PSI outperformed other pre-infusion metrics, including IFN-g co-culture cytokine intensity, ratio of CD4+ to CD8+ T cells, and various T cell phenotype frequencies.

PSI was the only metric that statistically differentiated responding from non-responding patients. The correlation of PSI with clinical outcome indicates the metric’s potential as a biomarker for guiding personalized CAR-T cell treatments and predicting therapeutic efficacy.1